Neuberger Berman Group
INSY

Neuberger Berman Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Neuberger Berman Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-23,900
Closed -$858K – 1619
2015
Q2 		$858K Buy
+23,900
New +$744K ﹤0.01% 1234

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Neuberger Berman Group's INSY Position: Q3 2015 in Review

Neuberger Berman Group sold out of Insys Therapeutics, Inc. (INSY) in Q3 2015, closing a stake of 23,900 shares — an estimated $858K sold.

Neuberger Berman Group first reported a position in INSY in Q2 2015 and held it in 1 quarter. The position peaked at $858K in Q2 2015. 145 funds tracked by Wall St. Rank hold INSY as of Q3 2015.

  • Neuberger Berman Group reported no remaining Insys Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Neuberger Berman Group sold 23,900 Insys Therapeutics, Inc. shares in Q3 2015, an estimated $858K.
  • Neuberger Berman Group first reported a position in Insys Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Neuberger Berman Group's Insys Therapeutics, Inc. position peaked at $858K in Q2 2015.
  • 145 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2015.

Based on Neuberger Berman Group's 13F filing for Q3 2015, filed 10 Nov 2015.